Skip to main content
Top
Published in: Infectious Diseases and Therapy 1/2021

Open Access 01-03-2021 | Soft Tissue Infection | Brief Report

Prospective Observational Study to Determine Kinetics of Procalcitonin in Hospitalized Children Receiving Antibiotic Therapy for Non-Critical Acute Bacterial Infections

Authors: Sophie E. Katz, Jennifer Crook, Rendie McHenry, Andras Szeles, Natasha Halasa, Ritu Banerjee

Published in: Infectious Diseases and Therapy | Issue 1/2021

Login to get access

Abstract

Introduction

The kinetics of procalcitonin in pediatric patients with non-critical acute bacterial infections receiving appropriate antibiotic therapy are not well described.

Methods

We performed a single-center, prospective observational pilot study of children admitted to a tertiary care children’s hospital who were receiving antibiotics for treatment of a non-critical acute bacterial infection, and we prospectively measured serial procalcitonin levels daily for 4 days during hospitalization.

Results

Among the 46 children with baseline procalcitonin levels enrolled in the study, procalcitonin kinetics followed a half-life of approximately 24 h in most patients. Procalcitonin declined faster than C-reactive protein over the first 48 h of appropriate antibiotic treatment. There was variation in biomarker levels among participants with the same infection type, especially in participants with bacteremia, musculoskeletal infection and skin/soft tissue infection.

Conclusion

Utility of procalcitonin as a biomarker to follow every 24–48 h in non-critically ill children receiving antibiotic therapy for bacterial infections as an objective measure of clinical improvement is promising.
Literature
2.
go back to reference Kuppermann N, Dayan PS, Levine DA, Vitale M, Tzimenatos L, Tunik MG, et al. A clinical prediction rule to identify febrile infants 60 days and younger at low risk for serious bacterial infections. JAMA Pediatr. 2019;173(4):342–51.CrossRef Kuppermann N, Dayan PS, Levine DA, Vitale M, Tzimenatos L, Tunik MG, et al. A clinical prediction rule to identify febrile infants 60 days and younger at low risk for serious bacterial infections. JAMA Pediatr. 2019;173(4):342–51.CrossRef
3.
go back to reference de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819–27.CrossRef de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819–27.CrossRef
4.
go back to reference Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600–7.CrossRef Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600–7.CrossRef
5.
go back to reference Downes KJ, Fitzgerald JC, Schriver E, Boge CLK, Russo ME, Weiss SL, et al. Implementation of a pragmatic biomarker-driven algorithm to guide antibiotic use in the pediatric intensive care unit: the Optimizing Antibiotic Strategies in Sepsis (OASIS) II study. J Pediatric Infect Dis Soc. 2020;9(1):36–43.CrossRef Downes KJ, Fitzgerald JC, Schriver E, Boge CLK, Russo ME, Weiss SL, et al. Implementation of a pragmatic biomarker-driven algorithm to guide antibiotic use in the pediatric intensive care unit: the Optimizing Antibiotic Strategies in Sepsis (OASIS) II study. J Pediatric Infect Dis Soc. 2020;9(1):36–43.CrossRef
6.
go back to reference Nobre V, Harbarth S, Graf J-D, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177(5):498–505.CrossRef Nobre V, Harbarth S, Graf J-D, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177(5):498–505.CrossRef
7.
go back to reference Schuetz P, Birkhahn R, Sherwin R, Jones AE, Singer A, Kline JA, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) study. Crit Care Med. 2017;45(5):781–9.CrossRef Schuetz P, Birkhahn R, Sherwin R, Jones AE, Singer A, Kline JA, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) study. Crit Care Med. 2017;45(5):781–9.CrossRef
8.
go back to reference Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55(5):651–62.CrossRef Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55(5):651–62.CrossRef
9.
go back to reference Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79(6):1605–8.PubMed Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79(6):1605–8.PubMed
10.
go back to reference Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998;24(8):888–9.CrossRef Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998;24(8):888–9.CrossRef
12.
go back to reference Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–67. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–67.
13.
go back to reference Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486–552.CrossRef Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486–552.CrossRef
14.
go back to reference McMichael BS, Nickel AJ, Christensen EW, Frenn KA, Truong WH, Laine JC, et al. Discriminative accuracy of procalcitonin and traditional biomarkers in pediatric acute musculoskeletal infection. Pediatr Emerg Care. 2020. McMichael BS, Nickel AJ, Christensen EW, Frenn KA, Truong WH, Laine JC, et al. Discriminative accuracy of procalcitonin and traditional biomarkers in pediatric acute musculoskeletal infection. Pediatr Emerg Care. 2020.
15.
go back to reference Florin TA, Ambroggio L, Brokamp C, Zhang Y, Rattan M, Crotty E, et al. Biomarkers and disease severity in children with community-acquired pneumonia. Pediatrics. 2020;145(6). Florin TA, Ambroggio L, Brokamp C, Zhang Y, Rattan M, Crotty E, et al. Biomarkers and disease severity in children with community-acquired pneumonia. Pediatrics. 2020;145(6).
16.
go back to reference Tsou P-Y, Rafael J, Ma Y-K, Wang Y-H, Raj S, Encalada S, et al. Diagnostic accuracy of procalcitonin for bacterial pneumonia in children—a systematic review and meta-analysis. Infect Dis. 2020;52(10):683–97.CrossRef Tsou P-Y, Rafael J, Ma Y-K, Wang Y-H, Raj S, Encalada S, et al. Diagnostic accuracy of procalcitonin for bacterial pneumonia in children—a systematic review and meta-analysis. Infect Dis. 2020;52(10):683–97.CrossRef
17.
go back to reference Damman J, Arias P, Kerner J, Zhang K-Y, Dehghan M, Krishnan G, et al. Procalcitonin as a predictive marker for bacteremia in children with a central line and fever. Hosp Pediatr. 2019;9(6):434–9.CrossRef Damman J, Arias P, Kerner J, Zhang K-Y, Dehghan M, Krishnan G, et al. Procalcitonin as a predictive marker for bacteremia in children with a central line and fever. Hosp Pediatr. 2019;9(6):434–9.CrossRef
18.
go back to reference Shaikh N, Martin JM, Hoberman A, Skae M, Milkovich L, Nowalk A, et al. Host and bacterial markers that differ in children with cystitis and pyelonephritis. J Pediatr. 2019;209(146–153):e1. Shaikh N, Martin JM, Hoberman A, Skae M, Milkovich L, Nowalk A, et al. Host and bacterial markers that differ in children with cystitis and pyelonephritis. J Pediatr. 2019;209(146–153):e1.
19.
go back to reference Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34(4):263–73.CrossRef Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34(4):263–73.CrossRef
20.
go back to reference Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006;32(3):469–72.CrossRef Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006;32(3):469–72.CrossRef
21.
go back to reference Shi Y, Xu Y, Rui X, Zhang H, Wang Y, Du W. Procalcitonin kinetics and nosocomial pneumonia in older patients. Respir Care. 2014;59(8):1258–66.CrossRef Shi Y, Xu Y, Rui X, Zhang H, Wang Y, Du W. Procalcitonin kinetics and nosocomial pneumonia in older patients. Respir Care. 2014;59(8):1258–66.CrossRef
22.
go back to reference Jenkins TC, Haukoos JS, Cotton E, Weitzenkamp D, Frank DN, Burman WJ. Time course of C-reactive protein and procalcitonin levels during the treatment of acute bacterial skin infections. Open Forum Infect Dis. 2018;5(3):ofy029. Jenkins TC, Haukoos JS, Cotton E, Weitzenkamp D, Frank DN, Burman WJ. Time course of C-reactive protein and procalcitonin levels during the treatment of acute bacterial skin infections. Open Forum Infect Dis. 2018;5(3):ofy029.
23.
go back to reference Bobillo S, Rodríguez-Fanjul J, Solé A, Moreno J, Balaguer M, Esteban E, et al. Kinetics of procalcitonin in pediatric patients on extracorporeal membrane oxygenation. Biomark Insights. 2018;13:117727191775190. Bobillo S, Rodríguez-Fanjul J, Solé A, Moreno J, Balaguer M, Esteban E, et al. Kinetics of procalcitonin in pediatric patients on extracorporeal membrane oxygenation. Biomark Insights. 2018;13:117727191775190.
24.
go back to reference Stockmann C, Ampofo K, Killpack J, Williams DJ, Edwards KM, Grijalva CG, et al. Procalcitonin accurately identifies hospitalized children with low risk of bacterial community-acquired pneumonia. J Pediatric Infect Dis Soc. 2018;7(1):46–53.CrossRef Stockmann C, Ampofo K, Killpack J, Williams DJ, Edwards KM, Grijalva CG, et al. Procalcitonin accurately identifies hospitalized children with low risk of bacterial community-acquired pneumonia. J Pediatric Infect Dis Soc. 2018;7(1):46–53.CrossRef
25.
go back to reference Alhinai Z, Elahi M, Park S, Foo B, Lee B, Chapin K, et al. Prediction of adverse outcomes in pediatric acute hematogenous osteomyelitis. Clin Infect Dis [Internet]. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa211/5780104. Accessed 31 Mar 2020. Alhinai Z, Elahi M, Park S, Foo B, Lee B, Chapin K, et al. Prediction of adverse outcomes in pediatric acute hematogenous osteomyelitis. Clin Infect Dis [Internet]. https://​academic.​oup.​com/​cid/​advance-article/​doi/​10.​1093/​cid/​ciaa211/​5780104.​ Accessed 31 Mar 2020.
26.
go back to reference Copley LAB, Barton T, Garcia C, Sun D, Gaviria-Agudelo C, Gheen WT, et al. A proposed scoring system for assessment of severity of illness in pediatric acute hematogenous osteomyelitis using objective clinical and laboratory findings. Pediatr Infect Dis J. 2014;33(1):35–41.CrossRef Copley LAB, Barton T, Garcia C, Sun D, Gaviria-Agudelo C, Gheen WT, et al. A proposed scoring system for assessment of severity of illness in pediatric acute hematogenous osteomyelitis using objective clinical and laboratory findings. Pediatr Infect Dis J. 2014;33(1):35–41.CrossRef
Metadata
Title
Prospective Observational Study to Determine Kinetics of Procalcitonin in Hospitalized Children Receiving Antibiotic Therapy for Non-Critical Acute Bacterial Infections
Authors
Sophie E. Katz
Jennifer Crook
Rendie McHenry
Andras Szeles
Natasha Halasa
Ritu Banerjee
Publication date
01-03-2021
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 1/2021
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-020-00358-7

Other articles of this Issue 1/2021

Infectious Diseases and Therapy 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.